INTRODUCTION
There are data both clinical and epidemiological which indicate that myocardial infarction is the main cause of death worldwide (Yusuf et al., 2005; Thygesen et al., 2007; Yeh et al., 2011) . Myocardial infarction can be induced by prolonged ischemia which as consequently affects cell viability and ultimately cardiac function. In addition, acute myocardial infarction can produce alterations in the topography of both the infarcted and noninfarcted regions of the ventricle (Pfeffer and Braunwald, 1990; Pfeffer, 1995) . There are some reports which indicate that the most effective method of limiting necrosis is restoration of blood flow; however, the effects of reperfusion itself may also be associated with tissue injury (Braunwald and Kloner, 1985; Kloner et al., 1989 ). In addition, some studies suggest that there are differences between both men and women in the myocardial response to ischemia/reperfusion injury (Wang, 2005) . These differences may be attributable to the effects of the sex hormones (Miejing et al., 2005; Delyani et al., 1996) . In this sense, there are studies which show that 17β-estradiol, but not 17α-estradiol, reduces myocardial necrosis in rabbits after ischemia and reperfusion (Hale et al., 1996) . Other studies suggest that 17β-Estradiol prevents dysfunction of canine coronary endothelium and myocardium and reperfusion arrhythmias after brief ischemia/reperfusion (Kim et al., 1996) . In addition, progesterone has been used in conjunction with estrogen in an ischemia/reperfusion model, resulting in a significantly decreased myocardial injury. The protective effect could be mediated by attenuation of inflammation and its possible interaction with endogenous estrogen (Dhote and Balaraman, 2007) . Other studies showed that a progestin (norethindrone acetate) can also reduce ischemia-reperfusion injury in ovariectomized monkeys receiving estrogen therapy previously (Suparto et al., 2005) . Nevertheless, there are reports which indicate that the administration of other progesterone derivative (medroxyprogesterone acetate) can inhibit the effects of estradiol that lead to protection of the myocardium from reperfusion injury and that this involves both neutrophil-dependent and neutrophilindependent mechanisms (Jeanes et al., 2006) . Apart from the above experiments, which also do not show clearly the cellular site and actual molecular mechanisms of progesterone and its derivatives, data are needed for characterizing the activity induced by this steroid on ischemia-reperfusion injury. To test this aspect, the present study was designed to investigate the effects induced by a progesterone derivative in a myocardial infarction/reperfusion model. In addition, it was thought desirable to evaluate the molecular mechanism involved in the activity of the progesterone derivative on left ventricular pressure, using some pharmacological tools for blocking various biological systems such as mifepristone [ et al., 1993) .
MATERIALS AND METHODS
The compounds evaluated in this study were purchased from Sigma-Aldrich Co., Ltd. The melting points for the different compounds were determined on an Electrothermal (900 model). A solution of progesterone (100 mg, 0.32 mmol), phenylhydrazine hydrochloride (90 mg, 0.62 mmol) in 10 mL of ethanol was stirred for 10 min at room temperature. Then 0.5 mL of hydrochloric acid was added and the mixture was stirred for 48 h at room temperature. The reaction mixture was evaporated to a smaller volume. After the mixture was diluted with water and extracted with chloroform. The organic phase was evaporated to dryness under reduced pressure, the residue was purified by crystallization from methanol:water (3:1).
Biological evaluation
All experimental procedures and protocols used in this investigation were reviewed and approved by the animal care and use committee of University Autonomic of Campeche (UAC) and were in accordance with the guide for the care and use of Laboratory Animals (Bayne, 1996) . Female rats (Wistar; weighing 200-250 g) were obtained from UAC.
Reagents
All drugs were dissolved in methanol and different dilutions were obtained using Krebs-Henseleit solution (≤ 0.01%, v/v).
Experimental design
Briefly, the female rat (200 -250 g) was anesthetized by injecting them with pentobarbital at a dose rate of 50 mg/Kg body weight. Then the chest was opened, and a loose ligature passed through the ascending aorta. The heart was then rapidly removed and immersed in ice cold physiologic saline solution. The heart was trimmed of non-cardiac tissue and retrograde perfused via a noncirculating perfusion system at a constant flow rate. It is important to mention that perfusion medium was the Krebs-Henseleit solution (pH 7.4, 37°C) composed of (mmol); 117.8 NaCl; 6 KCl; 1.75 CaCl2; 1.2 NaH2PO4; 1.2 MgSO4; 24.2 NaHCO3; 5 glucose and 5 sodium pyruvate. The solution was actively bubbled with a mixture of O2/CO2 (95:5). The coronary flow was adjusted with a variable speed peristaltic pump. An initial perfusion rate of 15 ml/min for 5 min was followed by a 15 min equilibration period at a perfusion rate of 10 ml/min. All experimental measurements were done after this equilibration period.
Perfusion pressure
Evaluation of measurements of perfusion pressure changes induced by drugs administration in this study were assessed using a pressure transducer connected to the chamber where the hearts were mounted and the results entered into a computerized data capture system (Biopac).
Inotropic activity
Contractile function was assessed by measuring left ventricular developed pressure (LVdP), using a saline-filled latex balloon (0.01 mm, diameter) inserted into the left ventricle via the left atrium. It is important to mention that latex balloon was bound to cannula which was linked to pressure transducer that was connected with the MP100 data acquisition system.
First stage

Ischemia/reperfusion model
After of 15 min equilibration time, the hearts were subjected to ischemia for 30 min by turning off the perfusion system (Booth et al., 2005) . After this period, the system was restarted and the hearts were reperfused for 30 min with Krebs-Henseleit solution. It is important to mention that hearts were randomly divided into 2 major treatment groups with n = 9: Group I. Hearts were subjected to ischemia/reperfusion but received vehicle only (Krebs-Henseleit solution). Group II. Hearts were subjected to ischemia/reperfusion and treated with progesterone derivative (0.001 nM) before ischemia period (for 10 min) and during the entire period of reperfusion.
It is important to mention that at the end of each experiment, the perfusion pump was stopped, and 0.5 ml of fluorescein solution (0.10%) was injected slowly through a sidearm port connected to the aortic cannula. The dye was passed through the heart for 10 s to ensure its uniform tissue distribution. The presence of fluorescein was used to demarcate the tissue that was not subjected to regional ischemia, as opposed to the risk region. The heart was removed from the perfusion apparatus and cut into two transverse sections at right angles to the vertical axis. The right ventricle, apex, and atrial tissue were discarded. The areas of the normal left ventricle non risk region, area at risk, and infarct region were determined using the technique reported by Boot et al. (2005) . Total area at risk is expressed as the percentage of the left ventricle.
Second stage
Effect induced by progesterone and progesterone derivative on perfusion pressure
Changes in perfusion pressure as a consequence of increases in time (3-18 min) in the absence (control) or presence of progesterone and its derivative at a concentration of 0.001 nM were determined. The effects were obtained in isolated hearts perfused at a constant-flow rate of 10 ml/min.
Evaluation of effects exerted by progesterone and progesterone derivative on coronary resistance
The coronary resistance in the absence (control) or presence of progesterone and its derivative at a concentration of 0.001 nM was evaluated. The effects were obtained in isolated hearts perfused at a constant flow rate of 10 ml/min. Since a constant flow was used, changes in coronary pressure reflect the changes in coronary resistance.
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Third stage
Effects induced by the progesterone derivative on left ventricular pressure through progestagen receptors
Intracoronary boluses (50 µl) of the progesterone derivative (0.001 to 100 nM) were administered and the corresponding effect on the left ventricular pressure was determined. The dose-response curve (control) was repeated in the presence of mifeprestone at a concentration of 1 nM (duration of preincubation with mifeprestone was by a 10 min equilibration period).
Effect exerted by the progesterone derivative on left ventricular pressure in the presence of α2 adrenergic blocker
The boluses (50 µl) of the progesterone derivative [0.001 to 100 nM] were administered and the corresponding effect on the left ventricular pressure was evaluated. It is important to mention that the bolus injection administered was done in the point of cannulation. The dose-response curve (control) was repeated in the presence of yohimbine at a concentration of 1 nM (duration of preincubation with yohimbine was by a 10 min equilibration period).
Effects induced by the progesterone derivative on left ventricular pressure in the presence of β2 adrenergic blocker
The boluses (50 µl) of progesterone derivative [0.001 to 100 nM] were administered and the corresponding effect on the left ventricular pressure was evaluated. The dose-response curve (control) was repeated in the presence of ICI 118,551 at concentration of 1 nM (duration of preincubation with ICI 118,551 was by a 10 min equilibration period).
Effects of progesterone derivative on left ventricular pressure in the presence of non-selective muscarinic receptor antagonist
The boluses (50 μl) of progesterone derivative [0.001 to 100 nM] were administered and the corresponding effect on the left ventricular pressure was evaluated. The dose-response curve (control) was repeated in the presence of atropine at a concentration of 1 nM (duration of preincubation with methoctramine was by a 10 min equilibration period).
Effects of progesterone derivative on left ventricular pressure in the presence of M2 receptor antagonist
The boluses (50 μl) of progesterone derivative [0.001 to 100 nM] were administered and the corresponding effect on the left ventricular pressure was evaluated. The dose-response curve (control) was repeated in the presence of methoctramine at a concentration of 1 nM (duration of pre-incubation with methoctramine was by a 10 min equilibration period).
Effects of progesterone derivative on left ventricular pressure in the presence of L-NAME
The boluses (50 μl) of progesterone derivative [0.001 to 100 nM] were administered and the corresponding effect on the left ventricular pressure was evaluated. The dose-response curve (control) was repeated in the presence of L-NAME at concentration of 1 nM mmol (duration of preincubation with L-NAME was by a 10 min equilibration period). 
Statistical analysis
The obtained values are expressed as average ± SE, using each heart (n = 9) as its own control. The data obtained were put under Analysis of Variance (ANOVA) using the Bonferroni correction factor (Hocht et al., 1999) . The differences were considered significant when p was equal or smaller than 0.05.
RESULTS
Chemical synthesis
The yielding of progesterone derivative was of 60% with melting point of 168-170°C. In addition, the spectroscopic analyses show signals for IR (Vmax, cm-1) at 3440, and 1720. In addition, the chemical shifts of the spectroscopic analyses of 1H NMR (Table 1) 
Biological activity
First stage
Effect of progesterone and its derivative on ischemia/ reperfusion: The results showed that progesterone derivative reduced infarct size expressed as a percentage of the area at risk compared with progesterone and vehicle-treated hearts (Figure 2 ).
Second stage
In In this study, the activity induced by the progesterone and its derivative on perfusion pressure and coronary resistance in the isolated rats heart were evaluated. The results obtained from changes in perfusion pressure as a consequence of increases in the time (3 to 18 min) in absence (control) or in presence of progesterone and its derivative (Figure 3 ), showed that progesterone derivative [1 nM] significantly decrease the perfusion pressure (p = 0.05) in comparison with the control conditions [1 nM]. Additionally, another result showed that coronary resistance, calculated as the ratio of perfusion pressure at coronary flow assayed (10 mL/min) was low in the presence of progesterone derivative than progesterone and the control conditions (p = 0.06) at a concentration of 1 nM (Figure 4) . Figure 5 shows that progesterone derivative decrease the left ventricular pressure in a dose dependent manner [0.001 to 100 nM] and this effect was not inhibited in presence of mifepristone at a dose of 1 nM. In addition, results showed that activity exerted by progesterone derivative [0.001 to 100 nM] decrease the left ventricular pressure and this effect was not inhibited in presence of yohimbine or ICI 118,551 (Figures 6 and 7) drugs at a concentration of 1 nM. On the other hand, results shown in the Figures 8 and 9 indicate that progesterone derivative induces a decrease in left ventricular pressure in a dose dependent manner [0.001 to 100 nM] and that this effect was inhibited by atropine (p = 0.06) and methoctramine (p = 0.05) at a dose of 1 nM. Finally, additional results (Figure 10) showed that the effect induced by the progesterone derivative [0.001 to 100 nM] on perfusion pressure in the presence of L-NAME (1 nM) was inhibited (p = 0.05). 
Third stage
DISCUSSION
Biological evaluation
There are studies which indicate that ischemia/reperfusion (I/R) injury occurs when a tissue is temporarily deprived of blood supply and the return of the blood supply triggers an intense inflammatory response (Park and Lucchesi, 1999; Arumugam et al., 2004) . Analyzing these data, in this study in the first stage, the effect of progesterone derivative was evaluated in an ischemia-reperfusion model. The results showed that progesterone derivative reduced infarct size expressed as a percentage of the area at risk compared with vehicle-treated hearts. This phenomenon can be conditioned by generation of some substances involved in endothelium of coronary artery (Bouis et al., 2001) or by the influence exerted by progesterone derivative on blood pressure which consequently bring reduction in the infarct size, and decrease the myocardial injury after ischemia-reperfusion similar to those reported with steroid derivatives (Beer et al., 2002) . In order to evaluate these hypotheses, we evaluated the effect of progesterone derivative on blood vessel capacity and coronary resistance translated as changes in perfusion pressure in isolated rat heart (Langendorff model). The results show that progesterone derivative significantly decreased the perfusion pressure over time (3-18 min) compared to the control conditions. These data suggest that progesterone derivative exerts effects on perfusion pressure which could subsequently modify vascular tone and coronary resistance. In this sense, the effects of progesterone derivative on coronary resistance were evaluated. We found that coronary resistance was decreased by the progesterone derivative. These data suggest that progesterone derivative exerts effect on vascular tone. To characterize the molecular mechanism of this phenomenon, we analyzed the reports of some investigations which indicate that progesterone induces its effect on blood pressure via activation of the progesterone receptor (Williams and Lefkowitz, 1977; Graham and Clarke, 1997) . For this reason, we used mifepristone, a progesterone receptor blocker (Watson et al., 1992) to determine if the effects of progesterone derivative on left ventricular pressure were via the progesterone receptor. It is important to mention that interaction of progesterone -(10,13-dimethyl-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-1H-8-aza-indeno[1,1b] -1H-cyclopenta[a]phenanthren-17-yl)ethanone (3). Reaction between progesterone (1) and Phenylhydrazine (2) to form 3. i = hydrochloric acid/rt. derivative with the progesterone-receptor may be a key requirement for the protective effect of this steroid on ischemic injury such as happening with activity exerted by other type of steroids (Hale et al., 1996) . Our results showed that the effects of progesterone derivative were not inhibited by mifepristone, suggesting that the molecular mechanism is not via the progesterone receptor.
Analyzing these results and other reports indicate that progesterone can regulate adrenal catecholamine synthesis (Lilley et al., 1976) , which has an important role in the development or maintenance of elevated blood pressure. Therefore, in this study the biological activity of progesterone derivative on left ventricular pressure in the absence or presence of yohimbine ( Figure 5 ) or ICI 118,551 (Figure 6 ) was evaluated. Our results showed that the effect of progesterone derivative was not inhibited by yohimbine or ICI 118,551, indicating that the molecular mechanism involved is not through adrenergic activity. Analyzing these results and other reports indicate that other progesterone derivative (progesteronecarbachol) induces activation of M 2 muscarinic which induces consequently a negative inotropic response and low blood pressure by activation of nitric oxide synthase (Figueroa-Valverde et al., 2012) . Therefore, in this study the activity of progesterone derivative on left ventricular pressure was evaluated in the absence or presence of atropine (Figure 7) . The results showed that the effect of progesterone-derivative on left ventricular pressure was inhibited in the presence of atropine. These results indicate that the effect of the progesterone derivative is via activation of the muscarinic receptor. Therefore, analyzing these experimental data, we also considered validating the effect of progesterone derivative on left ventricular pressure via the M 2 receptor. In this sense, in this study we evaluated the effect of progesterone- The progesterone derivative (0.001 to 100 nM) was administered (intracoronary boluses, 50 μl) and the corresponding effect on the perfusion pressure was evaluated in the absence and presence of L-NAME (1 nM). The results showed that activity induced by IP on perfusion pressure in presence of L-NAME was inhibited significantly (p = 0.05). The effect it is expressed as the area under the curve, and each bar represents the mean ± S.E. of 9 experiments. derivative in the absence or presence of methoctramine.
The results showed that the activity of progesterone derivative on left ventricular pressure in the presence of methoctramine was blocked significantly. These results show that the activity of steroid-derivate on left ventricular pressure involved indirect stimulation of the M 2 receptor. Nevertheless, to evaluate which vasoactive substance could also be involved in the changes induced by progesterone derivative on left ventricular pressure, we also validated the effect of the progesterone derivative on left ventricular pressure via nitric oxide. The effect of progesterone derivative in the absence or presence of L-NAME was evaluated. The results show that the effect of progesterone derivative on perfusion pressure was blocked in the presence of L-NAME. These data indicate that activity exerted by progesterone derivative on left ventricular pressure is through activation of nitric oxide synthase and increased production of nitric oxide leading to decrease of ischemia-reperfusion injury as reported with other type of steroids (Gabel et al., 2005) .
Abbreviations
EIMS, Electron Impact Ionization Mass Spectrometry; L-NAME, L-NG-nittroarginine methyl esther; IR, infrared spectra.
Conclusions
The experimental data obtained in this study suggest that progesterone derivative exerts its effect on left ventricular pressure via activation of the M 2 muscarinic receptor and this phenomenon also involves stimulation of nitric oxide synthase.
